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Neurological diseases have high prevalence globally and most are untreatable. 
Neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease 
(PO) are highly common especially with a growing elderly population. Alexander 
disease (ALX) is a rare neurodegenerative brain disease that typically affects infants, 
but has paralleling characteristics with AD, PD and Amyotrophic Lateral Sclerosis 
(ALS) including oxidative stress and neuronal degeneration. As a consequence ALX is 
much less researched. Using the large volume of research that has been done on AD, 
PO and ALS, this paper explores the possibility of using cellular antioxidant pathways, 
specifically the Nrf2-ARE pathway, to treat ALX. By utilizing the different 
experimental approaches taken in animal and cellular models of AD, PO, and ALS it is 
proposed that further research regarding the Nrf2-ARE pathway in ALX models is 
needed for its use for potential treatment. 
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Introduction  
Most neurological disorders and diseases have no prevention or effective 
treatments. According to the World Health Organization neurological diseases have the 
largest effect, through the calculation of disability-adjusted life years (DALYs), on 
populations worldwide in comparison to other systematic pathologies, such as 
respiratory and digestive diseases. DALYs can be thought of as loss of healthy life; one 
DALY is one year of healthy life lost. Neurological diseases account for 6.26 percent of 
the total DALYs.  Its effects include but are not limited to financial and caretaker 
burdens and loss of productivity. Not only are neurological diseases highly prevalent, 
but their global burden is expected to quadruple by 2030. 
Oxidative stress has been attributed as part of the pathogenesis in many diseases 
including neurodegenerative diseases. Nuclear factor E2-related factor 2 (Nrf2) is a 
transcription factor that regulates the antioxidant response element (ARE) pathway and 
is one of the major cellular defenses against neuronal degeneration and oxidative stress. 
This paper discusses oxidative stress’ effect and potential use of the Nrf2 pathway for 
treatment of Alexander disease (ALX), a rare genetic brain disease, while drawing on 
information of diseases with similar oxidative stressors: Alzheimer’s disease (AD), 
Parkinson's disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Even though these 
diseases exhibit different pathogenesis and symptoms they share common features, 
including neuronal degeneration, mechanisms of injury and their relationship to 
astrocytes. 
ALX, AD, PD and ALS all have a gradual clinical progression and neuronal 
degeneration that increase over time. All four of these diseases have aggregations 
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caused from misfolded proteins (17). Oxidative stress is believed to have a role in these 
abnormal aggregations and is hypothesized either to contribute to increased aggregation 
formation or the cause of the aggregation originally. Another significant similarity is the 
diseases’ connection to astrocytes. Astrocytes are glial cells that have recently been 
proposed to be an important factor in pathogenesis with AD, PD and ALS as well as 
presumably the main defect in ALX.  
The goal of this research is to suggest possible treatments for Alexander disease 
by looking at other brain diseases for which oxidative stress contributes to the 
underlying pathogenesis. AD, PD, and ALS have been researched to a greater extent 
due to the high prevalence of these diseases worldwide. Alexander disease on the other 
hand is not as extensively researched. Through the examination of scientific literature, 
potential treatments of Alexander disease is proposed by using the data being obtained 
about Nrf2 receptors through these well researched diseases. 
Background 
Oxidative Stress 
 Oxidative stress is highly prevalent in diseases in which age is a risk factor. 
According to Harman’s free radical theory, reactive oxygen species (ROS) cause 
damage to the mitochondria and other organelles which cause cells to age (48). 
Oxidative stress occurs when metabolic by-products are reactive to oxygen free 
radicals, such as singlet oxygen or oxidative secondary metabolites, which cause a 
disruption to protein folding and other structural abnormalities (13).  These metabolic 
by-products, called reactive oxidative species (ROS), can result in an imbalance of 
 
 
3  
redox couples. The human body has evolved mechanisms of combating ROS by the use 
of redox-dependent molecules and enzymes that buffer the excess free radicals. 
Oxidative stress occurs when there is an imbalance between the production of reactive 
oxygen species and the body’s ability to neutralize the free radicals. One example of a 
redox couple that is often seen in brain diseases is reduced and oxidized glutathione (see 
Figure 1). If oxidized glutathione is imbalanced and more abundant than its reduced 
couple than it cannot oxidize other molecules which could cause the cell to become 
toxic. This mechanism will be discussed further later in the paper.   
 
Figure 1: GSH as an antioxidant  
GSH reacts with radicals (RH/R) and donates an electron for the reduction of peroxides 
(ROOH). GSH is regenerated from GSSG through the glutathione reductase (GR) and 
NADPH (Figure referenced from (50)). 
The effect of oxidative stress in the pathogenesis of neurodegenerative diseases 
is highly pertinent in the discussion of potential treatments. The brain demands a lot of 
energy in comparison to other organs and has high levels of metabolic activity which 
results in an increased susceptibility to the formation of ROS. The brain has low levels 
of antioxidant activity, but is rich in enzymatically active transition metals which can 
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readily catalyze the formation of radicals. In an aging brain, there is even more risk for 
the development of ROS due to increasing inflammation and the body’s declining 
ability to degrade ROS (46, 44, 48) . 
Astrocytes 
Astrocyte dysfunction has been a new focus in neurobiology; its importance is 
especially seen in the study of neurodegenerative diseases.  Astrocytes are specialized 
glial cells that are responsible for support and structure in neurons. One of the 
mechanisms of astrocytes neuroprotection is glutathione secretion (29) which is 
discussed later in the paper.  Reactive astrogliosis is an increased amount of astrocytes 
in response to a disruption of balance in the brain usually triggered when there is 
neuronal death or injury in the nervous system. Too much astrogliosis can affect brain 
function and morphology. The role of astrocytes in neurological diseases is increasingly 
being studied and is becoming recognized as extremely important for brain homeostasis. 
The Nrf2 Pathway   
Nrf2 is a transcription factor that has been attributed to be a cellular defense 
against oxidative stress.  Exposure to oxidants, electrophiles and other activators 
stabilize Nrf2 in the cytoplasm allowing Nrf2 to be translocated into the nucleus. Once 
in the nucleus Nrf2 activates transcription of its target genes through the binding of 
AREs in its promoter region1. Through the activation of the Nrf2-ARE pathway 
hundreds of antioxidant genes are regulated including those involved in glutathione 
                                                        
1 ARE is a cis-acting regulatory element which is found in the promoter region of many genes. Nrf2 is 
responsible for activating antioxidant proteins through ARE in response to oxidative stress. At basal 
levels ARE is still responsible to expression of other genes (59, 82, 83). 
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synthesis and Phase II detoxification “stress-response” genes (11, 17). In the absence of 
oxidants and other activators Nrf2 activity is controlled by the cytosolic suppressor 
protein, Keap1, which promotes the ubiquitination and degradation of Nrf2 before it can 
be translocated into the nucleus (see Figure 2) 
Experiments with Nrf2 null mouse models have shown that neurons lacking 
Nrf2 are more likely to experience oxidative stress and undergo cell death. When 
overexpressing Nrf2, the antioxidant pathways were ‘saved’ by evidence of increased 
neuronal resistance to oxidative cell death (11, 47). The possibility of arresting 
premature oxidative stress using the Nrf2 pathway has been a focus of potential 
treatment in many diseases. Experimentation on why Nrf2 translocation to the nucleus 
is affected in some diseases is needed to understand more about the ARE pathway.  
Preventative methods and activator drugs for the Nrf2 pathway hold potential 
treatment options for many diseases including ALX. The overexpression of Nrf2 has 
limitations thus far. To date, manipulating the Nrf2 pathway has been more successful 
in prophylaxis than post-pathologic correction. There have been no successful trials of 
reversing pathological conditions seen in these diseases; data instead show a reduction 
of progressive neuronal death. Further understanding of oxidative stress and the Nrf2 
pathway could lead to more effective methods of protecting neurons and more effective 
treatments.  
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Figure 2: The Nrf2 pathway in astrocytes 
If Nrf2 is activated by ROS or small molecule activators Nrf2 will activate the ARE 
promoter region to allow the expression of antioxidant genes like GSH. Nrf2 binds as a 
heterodimer with a member of the small Maf (musculoaponeurotic fibrosarcoma 
oncogene) protein family (46). Based on information from (41, 43, 57, 59, 77) 
Glutathione  
Glutathione (gamma-glutamyl-cysteinyl-glycine; GSH) is a thiol2 that is 
abundant in cells and primarily is in the cytosol. GSH and glutathione disulfide (GSSG) 
                                                        
2 A thiol is a class of organic chemical compounds that are similar to alcohols but instead of an oxygen 
atom, contain a sulfur atom. The sulfur atom can be oxidized. 
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in an important redox couple that is important for oxidative defense, nutrient 
metabolism, and the regulation of cellular events (ie gene expression, cytokine 
production and immune response, etc.) (see Figure 1). Glutathione is synthesized from 
glutamate, cysteine and glycine which are catalyzed by two enzymes; gamma-
glutamylcysteine synthetase and glutathione synthetase (39). GSH is considered an 
antioxidant due to its ability to be oxidized by electrophilic substances, such as free 
radicals and ROS, and is also important for activating pathways that are responsible for 
limiting cell proliferation. Due to its presence in the cytosol GSH can be utilized rapidly 
if the cell is undergoing oxidative stress, which can deplete GSH levels. Diseased cells, 
as seen in AD, PD and ALS, will often have depleted levels of GSH in the brain (39). 
The basal and inducible levels of the enzymes that synthesize GSH are directly 
regulated by the Nrf2-ARE pathway (16). Astrocytes and other glial cells have higher 
levels of GSH than seen in neurons, making astrocytes critical for protection against 
oxidative stress in neurons (16, 29, 43). Neurons rely on the release of GSH by 
astrocytes for maintaining sufficient GSH levels. In degenerative diseases like AD, PD, 
and ALS, neurons need optimal levels of GSH for protection against free radicals 
released from the activation of microglia and astrocytes (33). Drugs that increase the 
synthesis of GSH are being targeted to combat oxidative stress in the brain through 
activation of the Nrf2-ARE pathway for AD, ALS and PD. 
Alexander Disease 
ALX was first described in 1949 by an Austrian pathologist, Dr. W.S. 
Alexander, and no more than 550 cases of ALX have been reported (2). ALX is 
characterized as a leukodystrophy, which is a white matter brain disease. White matter 
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contains myelinated neuronal axons insulated by myelin which serves to enhance 
neuronal transmission conduction velocity. Without myelin, these signal transmissions 
slow down or fail.  
 The first known case of ALX was found during the autopsy of a 
developmentally delayed infant.  Histological staining revealed protein aggregates 
found within astrocytes termed Rosenthal fibers.  Rosenthal fibers are the foundation of 
the diagnosis of Alexander disease and can now be visualized by MRI (4).  
ALX is more commonly found in infants, but there are some juvenile and adult 
cases. This disease is fatal and there is no treatment. Doctors can treat the symptoms but 
there is nothing to be done to stop the progressive destruction of white matter and 
buildup of Rosenthal fibers.  There are two categories of ALX; types I and II. Type I is 
the early-onset patients that typically show signs of seizures and developmental delays. 
The average lifespan of a type I patient is fourteen years. Type II is the late-onset 
patients that typically show signs of neuromuscular degeneration, such as loss of 
muscular control and coordination, difficulty swallowing and speaking, and excessive 
vomiting. The average lifespan of a type II patient is 25 years (5). 
Rosenthal fibers are composed of different types of proteins including αβ-
crystallin, heat shock protein 27 and glial fibrillary acidic protein (GFAP).  GFAP is an 
astrocytic intermediate filament protein that is important for the structure of astrocytes 
(17).  Ninety-five percent of ALX patients have the disease due to a gain-of-function 
mutation in the GFAP gene on chromosome 17 that overexpresses GFAP (1, 5). Nearly 
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all ALX mutations are due to an amino acid substitution and arise de novo3, occurring 
in the parental germ cell as opposed to early in development (5).    
In ALX, the toxicity of GFAP is attributed to oxidative stress and protein 
aggregation induced by a physiological response to mediate the overexpression of 
GFAP (7). Overexpression of GFAP in astrocytes creates functional abnormalities not 
only in the astrocyte but also affecting the surrounding neurons resulting in the 
degeneration of nearby myelinated neurons (4). In an experiment using Drosophila as a 
model organism, Wang et al., 2007 was able to rescue GFAP toxicity with antioxidant 
vitamin E supporting the hypothesis that oxidative stress has a role in ALX 
pathogenesis (7). 
Alzheimer’s disease 
Ninety-five percent of dementia cases found in people over the age of sixty-five 
are classified as late-onset AD. More than five million people in 2013 were living with 
AD in the US and old age is the number one risk factor. Less than five percent of AD 
cases are under the age of sixty-five, and are classified as early onset AD. Early onset 
AD has been attributed to genetics (2, 12). Although there is no cure for Alzheimer’s 
disease, there are treatments that slow down the development of the disease and many 
experimental treatments are being researched.  In 1976 AD was declared a substantial 
public health challenge by Doctor Robert Katzman. Physical characteristics of AD, 
beta-amyloid plaques and Tau tangles, were discovered in the 1980s4. 
                                                        
3 A de novo mutation is a genetic mutation that neither parent possesses, but is due to an error in cell 
division. This can occur in the parental germ cells or in other cells early in development.  
4  http://www.healthline.com/health-slideshow/alzheimers-history#1. Accessed on 2\5\14. 
 
 
10  
A common sign of AD is general memory loss. Patients usually visit the doctor 
once memory loss starts to affect their daily life. Other symptoms that are common 
include difficulty performing daily tasks, confusion on time or places and problems 
with speaking or writing. Over time, the symptoms increase to a severe cognitive 
decline where the patient can no longer control movement and need help with daily 
activities5. 
Amyloid beta-protein is the major component of the senile plaques found in AD 
patients.  Amyloid beta-protein is a 39-43 amino acid peptide derived from the cleavage 
of amyloid beta-protein precursor (APP). Abnormal cleavage of APP is attributed to 
aggregation of amyloid plaques. Beta-amyloid plaques are often found near degenerated 
neurons (13).   In mouse models, it has been found that elevated beta-amyloid levels 
cause a loss of synapses and decreased neuronal transmission (14). 
Tau protein under normal conditions is a microtubule-associated protein that 
regulates microtubule assembly and organization. In the brain, Tau is found in axons. It 
has been correlated with the regulation of axonal transport of organelles. When Tau is 
not phosphorylated normally, its affinity for microtubules decreases causing an 
accumulation in neurons which results in neuronal death or degeneration (15). 
Abnormal Tau accumulation is referred to as neurofibrillary tangles. 
Reactive astrogliosis is seen as an important factor in the pathology of AD, 
associated with amyloid beta plaques.  Astrocytes have been implicated in the 
mediation of amyloid beta peptides. It has been shown in in vivo APP/PS1 mouse 
models that astrocytes under stress will undergo chemotaxis and internalize amyloid                                                         
5  http://www.alz.org/ . Accessed on 2/5/14. 
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beta (16, 17).  Nrf2 levels were reduced in  AD postmortem brain tissue in hippocampal 
neurons which was attributed to Nrf2 not translocating to the nucleus as effectively (9, 
22). APP/PS1 mouse models showed reduced expression of Nrf2 through lower levels 
glutamine cysteine ligase (GCL) which is directly synthesized by the Nrf2-ARE 
pathway (44).  
Parkinson’s disease 
Parkinson’s disease (PD) affects about seven to ten million people worldwide, 
and 60,000 Americans are diagnosed with PD each year with ninety-six percent of the 
cases over the age of fifty (26). It is the second most common neurodegenerative 
disorder after AD (19). The cause of PD is still unknown, and old age is the number one 
risk factor of developing PD- similar to AD. Around twenty percent of the cases have a 
genetic component, which often leads to development of the disease at an earlier age. 
There are currently eleven known gene mutations that have been related to PD onset, 
with the most common one being the alpha-synuclein gene (18).  Diagnosis is based on 
patient symptoms because there is no test to accurately diagnose PD (26). Symptoms 
include resting tremors, slowed movements, gait impairment and postural instability, 
with late stages of the disease often causing cognitive decline and behavioral change 
(19). 
Development of the disease is due to dopaminergic cell loss within the 
substantia nigra. The substantia nigra is an important motor center that is responsible for 
producing dopamine, a neurotransmitter that functions in motor control and also acts as 
a hormone. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is an inhibitor  of 
complex I of the electron transport chain in mitochondria that shows implications in 
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dopaminergic pathway damage. Along with dopaminergic cell loss, Lewy bodies, which 
were first described in 1912 by Freidrich Lewy are another distinguishing hallmark of 
PD (19). Lewy bodies are alpha-synuclein-immunoreactive aggregations found within 
neuronal processes (18).   
Evidence derived from postmortem analysis of PD brain tissue show increased 
levels of oxidized protein levels, lipids and nucleic acids implicating oxidative stress 
involved in the mechanism of injury (34). In vitro experiments indicate that 
accumulation of alpha-synuclein collected within astrocytes often resulted in neuronal 
death (17). Abnormal levels of Nrf2 have not been seen within PD cells, but Nrf2 null 
mice in Parkinson models showed increased sensitivity to damage of the dopaminergic 
pathway, increased protein aggregation and neuronal death (9, 32, 34). 
Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis (ALS), also referred to as Lou Gehrig’s disease, 
is a progressive neurodegenerative disease that affects motor neurons. ALS affects 5 1,000,000�  people worldwide. Patients with the disease typically have asymmetric 
weakness of the extremities or facial and lingual muscle weakness in the head 
(difficulty swallowing, talking, etc.).  ALS usually does not affect the senses or the 
ability to think and reason (28). The average age of onset is 56. With a familial history, 
the average age lowers to 46 years and only ten percent of the cases are linked to 
genetics.  The average lifespan is three years after diagnosis (27).  There are no known 
risk factors for developing ALS except for the small genetically attributed percentage. 
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There are many gene mutations that are associated with familial and sporadic ALS 
including SOD1 and C9orf72 (27). 
Diagnosing ALS is difficult because there is no test that confirms the disease, 
and there is still not much known about injury mechanism of motor neurons. Diagnosis 
is based on symptoms and a series of tests that rule out other diseases. There is no cure 
for the disease, but patients are treated symptomatically.  Currently there is a 
medication called Riluzole that helps slow the pathogenesis, but only temporarily 
(28).  The disease is classified by the degeneration and loss of motor neurons in the 
cranial nerves VII (facial), X (vagus), XI (accessory) and the hypoglossal nucleus (IX). 
Degeneration of motor neurons stops transmission from motor neurons to muscles, 
causing them to atrophy over time. Eventually, this will lead to respiratory failure due to 
failure of the diaphragm and chest. Another characteristic of ALS is the loss of axons 
and decreased myelin as seen in ALX. Histologically Lewy, Bunina6 and ubiquitinated 
bodies are found in the cytoplasm of motor neurons (27). As similar to ALX, PD and 
AD, ALS is still not fully understood by the medical community and research is being 
done regarding why and how the disease occurs. 
The potential importance of treatments using the Nrf2-ARE pathway is 
emphasized by the evidence that there is a reduction of Nrf2 mRNA and protein levels 
and increased levels of Keap1 mRNA in postmortem brain tissue from ALS patients 
(24, 31, 49). Levels of glutathione are decreased in ALS animal models as well as 
postmortem brain tissue from ALS patients which could further implicate the Nrf2 
pathway in the injury mechanism (29). This notion was consistent with the observation                                                         
6 Bunina bodies are neuronal inclusions (like Lewy bodies) but with different histological characteristics 
(27).  
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that ALS mouse models had neuronal degeneration associated with nearby degenerated 
astrocytes (17).  
Methods 
Scientific journal articles that outline the detail and data of experiments 
regarding the above neurodegenerative disorders and Nrf2 receptors were used to 
formulate new ways to look at ALX potential treatments. Articles that were used have 
1) information on one of the mentioned neurodegenerative diseases, 2) information 
linking Nrf2 experimental research to the diseases, 3) data from the experiment in the 
form of tables, graphs and figures and 4) current articles published within the last ten 
years. 
Currently there is very little experimental data on the use of Nrf2 receptors for 
ALX. When searching for AD, PD and ALS there is at least ten times the amount of 
information implicating Nrf2 receptors as a future treatment than with ALX.  The bulk 
of these articles may be found on the US National Library of Medicine database through 
PubMed.  Limitations on this method of gathering data include the availability of the 
articles through PubMed. Some of the article unavailable on PubMed can be found 
through the University of Oregon’s library through the use of interlibrary loans. As a 
result of relying on the data from other experiments as opposed to collecting my own 
limited the conclusions that I was able to make on ALX.            
Discussion                                                                                                                                                                                                                                                                                                                                                                                                              
Nrf2 expression and stabilization is effective for combating oxidative stress and 
neurodegeneration seen experimentally in AD, PD, and ALS (31). Overexpression can 
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be achieved through the disruption of the Keap1-Nrf2 interaction or through the genetic 
overexpression of the Nrf2 pathway. This section will discuss how the Nrf2 pathway 
has been targeted for therapy in AD, PD, and ALS and how it can be applied to ALX. A 
summary of the experiments discussed in this paper is outlined in Table 1.  
Literature Review of ALX and the Nrf2 Pathway  
There has been little literature published regarding ALX and the Nrf2 pathway. 
One of these articles, published in 2012 by Daniels et al., 2007, discusses the reduction 
of GFAP using overexpression of the Nrf2 transcription factor in R236H GFAP mouse 
models (8). Overexpression was controlled by a GFAP promoter, which allowed Nrf2 
overexpression to be targeted in astrocytes. Five brain regions were examined including 
the hippocampus, cortex, olfactory bulb, brain stem and cervical spinal cord. Decreased 
GFAP and Rosenthal fibers due to astrocytic overexpression of Nrf2 were found in all 
regions tested except the cervical spinal cord when compared to the controls (8).  
A finding that was significant is that the overexpression of Nrf2 in astrocytes 
does not affect GSH levels even though Nrf2 regulates its expression. This is important 
because GSH depletion is speculated to affect the pathogenesis of other 
neurodegenerative diseases discussed. There are several potential explanations proposed 
for this finding: 1) GSH levels do not affect the pathogenesis in ALX, 2) there is 
enough Nrf2 initially to provide sufficient GSH levels or 3) the beneficial effects of 
Nrf2 on GFAP seen in this experiment are not mediated through GSH (8). AD, PD and 
ALS do not have injury mechanisms that affect astrocytes directly as seen in ALX so it 
is logical to infer that ALX defects do not affect GSH levels.  
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In another article that was also published in 2012 regarding ALX, the Nrf2 
transcription factor was knocked out in GFAP mutant and transgenic mouse models to 
determine its effect on the pathology of ALX (30). The results demonstrated 
surprisingly little change. Life span and distribution of Rosenthal fibers were relatively 
unchanged with the absence of Nrf2. Microglial activation and astrocyte reactivity was 
significantly reduced in the knockout mice (30). An experiment done by Hubb et al., 
2007 investigated how Nrf2 affects the brain (36). The effect of knocking out the Nrf2 
pathway was tested on mice. Nrf2- null mice presented widespread astrocytic activation 
with excess GFAP and myelin degeneration. There was no neuronal cell damage, but 
formation of spaces in white matter of the brain. It was concluded that Nrf2 has an 
important role in myelin homeostatic maintenance (36).  
Defects in Nrf2 mouse models are synonymous with those seen in ALX models, 
but with an ALX mutant mouse, a lack of Nrf2 showed no harmful or beneficial effects 
(30). The lack of response with a loss of Nrf2 suggests that there already is a lack of 
Nrf2 stabilization in ALX cells, whereas overexpression of Nrf2 showed beneficial 
effects.  These articles are insufficient to support the hypothesis that Nrf2 could provide 
therapeutic benefits for ALX patients, but both stress that further experimentation may 
provide insight into potential treatment options.  
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Table 1: A list of experiments utilizing the Nrf2-ARE pathway  
Astrocytic Expression of Nrf2 
Chen et al., 2009 showed that astrocytic Nrf2 activation, under the control of the 
GFAP promoter, protects neurons in the MPTP7 mouse model of PD (34). MPTP 
treatment in the mouse model decreased Nrf2-ARE signaling and increased cellular 
sensitivity to stress. This model also showed that the GFAP-Nrf2 transgene expressed 
within astrocytes protected against MPTP toxicity and levels of striatal dopamine were 
increased. Based on these data, astrocytic Nrf2 activation was sufficient to protect 
against MPTP toxicity (34).                                                          
7 MPTP is a neurotoxin that causes permanent symptoms of PD in animal models. It is widely used in PD 
experiments, because it quickly causes PD symptoms (69). 
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Vargas et al., 2008 found that activating Nrf2 in astrocytes resulted in an up 
regulation of antioxidant defenses, protection against neighboring neurons in an hSOD1 
mouse model of ALS, and a counteraction of neuronal degeneration (29).  Nfr2 was 
overexpressed by using the GFAP promoter in astrocytes, and astrocyte toxicity 
expressing the hSOD1 mutant was reversed seen through the nearby intact motor 
neurons. Overexpression of Nrf2 resulted in increased glutathione secretion by 
astrocytes and increased life span of the mutant mouse model. It was concluded that 
GSH is a key antioxidant component of the ALS animal model (29).  
Up regulation of Glutathione 
Steele et al., 2013 compares four known Nrf2 activators to investigate which 
produced the greatest release of GSH by astrocytes; R-alpha-Lipoic acid, tert-
butylhydroquinone, sulforaphane, and Polygonum cupidaturn extract containing 50% 
resveratrol (33). It was found that all these activators caused an increase in GSH levels 
with sulforaphane having the greatest effect by a factor of 2.4 (33). Another part of this 
experiment was to measure the cleavage of GSH to cysteinylglycine by astrocytes. 
Sulforaphane again demonstrated the greatest effect increasing cysteinylglycine levels 
by a factor of 1.7.  Cysteinylglycine maintains an optimal level of GSH intracellularly, 
so it was important to monitor expression of cysteinylglycine as well as GSH (33). Even 
though GSH expression may not be important in the pathogenesis of ALX, it still 
provides a means to monitor the expression of Nrf2. This experiment provides evidence 
that sulforaphane is a potent activator of the Nrf2-ARE pathway.  
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Delivery of Treatment 
Farr, et al., 2014 showed that the use of a phosphorothionated antisense 
oligonucleotide8 directed at GSK-3-beta suppression reduced oxidative stress by 
increasing Nrf2 transcriptional activity (20). GSK-3-beta, glycogen synthase kinase, is a 
pleiotropic enzyme9 that negatively regulates Nrf2. Its function in the brain is 
phosphorylation of Tau and when hyperphosphorylated results in NFT 
generation. SAMP8 AD mouse models were used to test the antisense oligonucleotide 
through intracerebroventricular10 delivery. It was found that the antisense not only 
reduced oxidative damage by upregulation of the Nrf2-ARE pathway, but also 
improved cognition. The GSK antisense oligonucleotide also demonstrated a capacity to 
cross the blood brain barrier, indicating that this research may have potential application 
in peripheral delivery (20). 
Williamson et al., 2012 showed evidence that knockdown of Keap1 in 
astrocytes protects neurons from oxidative stress-induced cell death (35). By using short 
interfering RNA (siRNA)11 to silence Keap1 in astrocytes, it was noted that a 
significant increase in levels of genes expressed by the Nrf2-ARE pathway occurred, as 
well as the upregulation of the Nrf2-ARE pathway in the ARE-hPAP reporter (p1) 
mouse model. siKeap1 astrocytes also resulted in greater protection of neurons from 
oxidative stress-induced cell death (35). Results from in vitro experiments showed that                                                         
8 An oligonucleotide is a short nucleic acid polymer that can readily bind complementary nucleotides. 
Antisense oligonucleotides as described in this paper are single stranded RNA or DNA that are 
complementary to a targeted sequence to suppress expression of a gene or protein. 
9 A pleiotropic enzyme means that it is involved in a variety of cellular activities. 
10 Intracerebroventricular delivery is the administration of drugs or chemicals through the ventricular 
system of the brain.  
11 siRNA is a class of small double stranded RNA that can be used to interfere with translated of targeted 
proteins.  
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targeting Keap1 using siRNA has therapeutic potential for neurodegenerative disorders, 
but safe delivery needs to be developed.  Intravascular delivery across the blood brain 
barrier has been attempted and thought possible, but it is still highly experimental (35). 
Nanou et al., 2013 used lentiviral delivery12 to induce overexpression of Nrf2 
genes in in vitro experiments as well as in ALS mouse models (49). The cellular models 
indicate delayed disease onset and increased survival time when Nrf2 overexpression 
was specifically targeted to astrocytes.  Cells expressing the virally delivered Nrf2 gene 
had a significant decrease in oxidative stress levels in comparison to the control. When 
viral delivery was attempted by injection in muscle tissue of mice in vivo, there was 
little change between the wild type and the ALS model. These results indicate that the 
administration needs to be more widespread within the central nervous system (49). 
Other lentiviral deliveries were found successful in AD mouse models by Kanninen et 
al., 2008, 2009 (44, 45). Lentiviral vector encoding human Nrf2 was protective against 
amyloid-beta toxicity and was sustained for up to six months. The effects of Nrf2 
upregulation were dispersed beyond the direct injection as seen in the ALS model, but 
muscular injection was not attempted (44, 45).  
Lastres-Becker et al., 2014 demonstrated that overexpression of chemokine 
fractalkine (CX3CL1) with adeno-associated viral vectors13 activates the Nrf2-ARE 
pathway, and attenuates Tau defects induced by microgliosis (23). CX3CL1 is a 
chemokine that is found in astrocytes and neurons and participates in the prevention of 
inflammation. In animal models of AD, CX3CL1 is expressed in Tau-injured neurons as                                                         
12 Lentiviruses can deliver viral RNA into the DNA of host cells. One of the unique characteristics of this 
delivery method is that lentiviruses can infect non-dividing cells.  
13 Adeno-associated viral vectors are single stranded DNA viruses that insert genetic material into the  
DNA.  
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well as other stressed cells. CX3CL1 attenuates microglial activation via Nrf2 activation 
in order to mediate inflammation. It was hypothesized that this is due to an increased 
Nrf2 protein stability through suppression of GSK-3-beta by CX3CL1. The results 
suggest that CX3CL1 as an activator of antioxidant genes by inducing Nrf2 is a viable 
factor to reduce oxidative stress (23). 
Neymotin et al., 2011 examined two triterpenoids14 that would potentially 
activate the Nrf2-ARE pathway in cell cultures and mouse models of ALS (31). Treated 
mouse models were found to have a slowed disease progression using the triterpenoid, 
CDDO-TFEA (2-cyano-3,12-dioxool-eana-1,9-dien-28-oic-
trifluroethylamide).  CDDO-TFEA was able to penetrate the blood-brain-barrier in the 
mouse models. CDDO-TFEA was delivered through the stomach after being dissolved 
in oil (31).  
Other triterpenoids have been tested for reducing oxidative stress levels, 
including CDDO-MA (2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid-methylamide) 
in AD and PD. In a study with AD mouse models there was no direct upregulation of 
Nrf2, but an upregulation of enzymes that are associated with Nrf2. Decreased signs of 
microgliosis and oxidative stress were found, as well as reduced levels of amyloid 
plaques (37). CDDO-MA was also tested with PD mouse models and found to be a 
potent inducer of Nrf2 effecting GSH oxidation and reduction in a neuronal cell line 
(38). One benefit of the use of triterpenoids is its ability to safely activate Nrf2 target 
genes. All experiments done with triterpenoids were delivered orally and found to have 
high levels in the brain suggesting that it readily crosses the blood-brain barrier.                                                         
14 Triterpenoids come from a class of hydrocarbons and are able to form cyclic structures. It is found in 
plans and essential oils.  
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Conclusions  
Overexpression of Nrf2 as an activator of the antioxidant pathway is a common 
theme in the literature regarding its potential use in treatment of neurodegenerative 
diseases. Abundant Nrf2 may be an effective way to increase expression of antioxidant 
genes due to titration of Keap1. If Keap1 cannot keep up with degradation of Nrf2, than 
more Nrf2 will be able to translocate to the nucleus, which allows the synthesis of 
antioxidant genes (see Figure 2). There is no evidence that the Nrf2 pathway is 
inhibited in ALX, but overexpression of Nrf2 may allow constitutive expression of 
antioxidant genes and provide protection against oxidative stress.  
One thing that is unique to experimentation with Nrf2 in neurodegenerative 
diseases is that expression is specifically altered in astrocytes. Because GFAP defects in 
ALX originate within astrocytes, overexpression of Nrf2 in astrocytes will be an 
important factor to study. Many compounds have been identified that induce Nrf2 
transcription in astrocytes, but delivery is a common limitation in treatment application. 
Many activators that are highly effective have no known mechanism for safe delivery. 
Compounds like triterpenoids, CX3CL1 and sulforaphane are strong candidates to test 
in ALX animal models, as well as the use of antisense oligonucleotides and siRNA. 
The potential to use the Nrf2-ARE pathway to treat neurodegenerative diseases 
including ALX is important. Because ALX defects largely affect myelin and astrocytes, 
the use of increased expression of Nrf2 is viable when there is evidence that a lack of 
Nrf2 is detrimental to myelin and astrocyte function. Protein aggregations similar to 
those seen in ALX have been decreased in AD, PD, and ALS by modulating Nrf2 
which suggests that similar techniques should be tested on ALX mouse models. Daniels 
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et al., 2012 provides evidence that overexpression of Nrf2 is successful in ALX, but 
further experimentation is needed. The potential for astrocytic Nrf2 overexpression is 
viable and should be further tested using different methodologies of delivery that would 
be safe for future clinical use. 
Gene therapy is a growing field in treatment and prevention in many diseases 
including genetic diseases and immune deficiencies. One limitation is the difficulty to 
find a way for the transgene to be expressed in the target body system using a safe 
method of delivery. Gene therapy through the Nrf2-ARE pathway holds great potential 
in neurodegenerative diseases, including ALX. Not only may gene therapy be 
successful in treating ALX, but through ALX’s unique connection to astrocytes, it may 
provide a further understanding of the Nrf2-ARE pathway in the brain and specifically 
in astrocytes.  
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